AASLD2016[1827] 自发和治疗乙型肝炎表面抗原血清学缺失临床结

StephenW

1827
Clinical outcomes after spontaneous and nucleos(t)ide analogues (NUCs)-treated hepatitis B surface antigen(HBsAg) seroclearance in chronic HBV infection are
favourable
Xiang-yong Li1, Changhao Zhu1, Xu You2, Yuankai Wu1, Yutian
Chong1; 1The department of the infectious desease, The Third Affiliated
Hospital of SUN Yat-sen University, Guangzhou, China; 2the
third affiliated hospital of Southen Medical University, Guangzhou,
China
Objects To investigate the long-term clinical outcomes and
durability of HBsAg seroclearance following nucleos(t)ide analogue
(NUC) therapy or without antiviral treatment in patients
with chronic HBV infection. Methods we retrospectively analyzed
9335 patients with chronic HBV infection who was
treated with nucleos(t)ide analogues or without antiviral treatment
during a median follow-up period of 6.3 years, and a
total of 158 patients achieved HBsAg seroclearance. Results
During follow-up for 2620 CHB patients who didn’t receive
antiviral treatment, 54 patients acquired HBsAg seroclearance.
The average time for acquiring HBsAg seroclearance
was 5.5 (020) years. 16 cases of whom acquired HBsAg/
HBsAb seroconversion, one patient returned HBsAg positive.
HBeAg seroclearance in HBeAg-postive patients occured in 9
patients, and the rate of HBeAg/HBeAb seroconversion was
57.1% (8/14). The virological breakthrough was occurred in
one patient (1.9%). None developed into liver cirrhosis, liver
carcinoma or died. During follow-up for 6715 CHB patients
who received NUC treatment, 104 patients acquired HBsAg
seroclearance. The average time for acquiring HBsAg seroclearance
was 6.6 (0.514) years. HBsAg seroconversion
occured in 29 patients, and one patients returned HBsAg positive.
The rate of HBeAg seroclearance was 88.2%(30/34),
and HBeAg/HBeAb seroconversion occured in 27 patients.
No patient developed virological breakthrough. There were
28 cases discontinued the NUCs treatment. 3 cases of 104
patients with HBsAg seroclearance got disease progression,
1 case developed into compensated cirrhosis from the initial
imaging diagnosis of CHB, and 2 cases developed into liver
carcinoma from the initial diagnosis of decompensated liver
cirrhosis; no death occurred among the patients. Conclusion
HBsAg seroclearance in chronic HBV infection with or without
antiviral treatment was associated with favourable clinical outcomes
in most cases during long-term follow-up.
Disclosures:
The following people have nothing to disclose: Xiang-yong Li, Changhao Zhu, Xu
You, Yuankai Wu, Yutian Chong

StephenW

AASLD2016 [1827]
自发和治疗乙型肝炎表面抗原血清学缺失临床结果
ide类似物（NUC）治疗乙型肝炎表面抗原
HBsAg）慢性HBV感染的血清学缺失
慢性HBV感染中自发和核苷类似物（NUC）治疗的乙型肝炎表面抗原（HBsAg）血清清除后的临床结果是
有利
李祥龙1，张昊朱1，徐友2，Yuankai Wu1，Yutian
Chong1; 1传染病部，第三附属机构
中国广州中山大学医院; 2
Southen医科大学第三附属医院，广州，
中国
对象调查长期临床结果和
核苷（t）类似物后HBsAg血清清除的耐久性
（NUC）治疗或没有抗病毒治疗
与慢性HBV感染。方法我们回顾性分析
9335例慢性HBV感染患者
用核苷（t）ide类似物处理或无抗病毒治疗
在中位随访期为6.3年，a
共有158例患者达到HBsAg血清清除率。结果
在随访期间2620例CHB患者未接受
抗病毒治疗，54例患者获得HBsAg血清清除。
获得HBsAg血清清除的平均时间
是5.5（020）年。其中16例获得HBsAg /
HBsAb血清转换，一名病人返回HBsAg阳性。
HBeAg阴性患者HBeAg血清清除发生于9
患者，HBeAg / HBeAb血清学转换的发生率
57.1％（8/14）。病毒学突破发生在
一个病人（1.9％）。没有发展成肝硬化，肝脏
癌或死亡。随访期间6715例CHB患者
谁接受NUC治疗，104例患者获得HBsAg
seroclearance。获得HBsAg血清清除的平均时间
是6.6（0.514）年。 HBsAg血清转化
发生于29例患者，1例返回HBsAg阳性。
HBeAg血清清除率为88.2％（30/34），
和HBeAg / HBeAb血清转换发生在27例患者。
没有病人发展病毒学突破。曾经有
28例停止NUCs治疗。 3例104
HBsAg血清清除的患者出现疾病进展，
1例从初始发展成为补偿性肝硬化
成像诊断CHB，2例发展为肝
癌从初始诊断失代偿肝
肝硬化在患者中没有发生死亡。结论
HBsAg血清清除在慢性HBV感染有或无
抗病毒治疗与有利的临床结果相关
在大多数情况下在长期随访期间。
披露：
以下人士没有透露：李向勇，朱长豪，徐
你，吴玉凯，尤玉田